HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.
about
FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locusDiagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancerValue of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case-control studyNeutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer.Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy.Male breast cancer: A retrospective study comparing survival with female breast cancerBiological markers and response to neoadjuvant taxane-based chemotherapy in patients with locally advanced breast cancer.Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer.Optimizing conservative breast surgery.The relationship between transcription initiation RNAs and CCCTC-binding factor (CTCF) localization.Increased expression of senescence markers p14(ARF) and p16(INK4a) in breast cancer is associated with an increased risk of disease recurrence and poor survival outcome.Poorer survival of male breast cancer compared with female breast cancer patients may be due to biological differences.A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy.Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.
P2860
Q24319845-B87B7B25-D00F-400F-8CE2-C0609813DF04Q30315973-597BE218-EB68-4EC6-A588-75DEB2C88A1EQ33480671-D9F2BC41-370C-48BF-9484-C81D895B3C94Q34299177-9F1B33D8-922B-40B6-A9EC-F2DBBA74D0FFQ34328227-5F5E0A93-8225-455A-B7A2-DF506392BBF3Q34434819-07389C57-B208-4E58-975D-0D14C1BD534AQ34440998-8FF59E3E-66CA-4533-A03B-7A5A2CA2D521Q35237197-FB30758B-E595-4323-9B17-2F5C4F495F56Q36092023-6DB70A8A-D014-4F0C-8D8B-3C2548A19519Q36423949-72964B93-7107-45A4-BD9C-C88462A453C2Q36505849-DC0F9AD3-8686-41AD-A842-F734CA40CDD1Q36787344-9984CC8F-6433-49B6-A8E9-B605D58BFC70Q37276706-A8E56046-4C1A-4171-B400-74C274D266CFQ37584869-BF2921BB-10BB-4063-AEA6-FD42B78632DAQ37845308-43DC3140-C38A-4F2A-906B-F276940A5541Q38365167-99210439-030D-4437-92CA-2D2AE4DF6672Q40932260-56D7418A-9987-4757-BBF9-B91767EED105Q45851310-A90C7C09-360D-4461-9E3A-513A1144FD02Q46435201-1CA41492-C573-4A96-9D34-C8B810B0E031Q46881099-9695FADD-4FD1-43AD-B05D-89B6A6C6C6FFQ53150503-62FD04E2-B17F-432B-9175-75025F0B5FB9Q54240384-55C4AD62-0EA7-4C00-A35B-15C47CFFBDDDQ54649694-273A3440-0CEA-4BDF-9B11-983D5F7F968FQ55073332-3F06834F-B319-48B8-AB43-D965F6F4BA03
P2860
HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
HER-2, p53, p21 and hormonal r ...... l plus epirubicin combination.
@ast
HER-2, p53, p21 and hormonal r ...... l plus epirubicin combination.
@en
type
label
HER-2, p53, p21 and hormonal r ...... l plus epirubicin combination.
@ast
HER-2, p53, p21 and hormonal r ...... l plus epirubicin combination.
@en
prefLabel
HER-2, p53, p21 and hormonal r ...... l plus epirubicin combination.
@ast
HER-2, p53, p21 and hormonal r ...... l plus epirubicin combination.
@en
P2093
P2860
P356
P1433
P1476
HER-2, p53, p21 and hormonal r ...... l plus epirubicin combination.
@en
P2093
Alfredo Ribeiro-Silva
Fábio E Zola
Heitor R C Marana
Marcelo G Tiezzi
P2860
P2888
P356
10.1186/1471-2407-7-36
P407
P577
2007-02-26T00:00:00Z
P5875
P6179
1046340993